Restorative and health-Enhancing Sleep Time (REST)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Advanced Research Projects Agency for Health (ARPA-H), under the National Institutes of Health, is seeking proposals for the Restorative and health-Enhancing Sleep Time (REST) program. This Solicitation (ARPA-H-SOL-26-159) aims to transform sleep health by developing objective, home-based, closed-loop technologies to measure and treat poor sleep, specifically insomnia. The program seeks to establish a foundation for personalized sleep health technologies that improve long-term health outcomes at scale.
Scope of Work
The REST program focuses on two Technical Areas (TAs):
- TA1: Measure & Diagnose: Develop validated, in-home systems for objective measurement of sleep-relevant physiology, diagnosis of poor sleep (centered on insomnia), and classification of mechanistic sleep subtypes. This includes hardware/software development, clinic-to-home translation, and in-home diagnostic capabilities.
- TA2: Control & Treat: Develop noninvasive, closed-loop systems that use real-time physiological measurements to personalize and deliver interventions during sleep to improve sleep quality and treat insomnia. This involves real-time neuromodulation, multi-microstructure targeting, and mechanism-informed treatment. Shared non-solicited program resources, including Foundational Sleep Health Modeling and Discovery, a Research Integrator, and Independent Verification & Validation (IV&V), will support the program.
Contract & Timeline
- Award Instrument: Other Transaction (OT) agreements.
- Period of Performance: 66 months (5.5 years), structured into three phases: Prove Core Technical Thesis (24 mos), Demonstrate Proof-of-Concept (18 mos), and Clinical Translation and Commercialization Preparation (24 mos).
- Solution Summary Submission Deadline: August 12, 2026, at 12pm ET.
- Published Date: June 16, 2026.
- Proposer's Day: July 13, 2026.
Eligibility & Set-Aside
ARPA-H encourages proposals from commercial performers, academic institutions, and non-profit organizations. Federally Funded Research and Development Centers (FFRDCs) and government entities are not permitted to respond as prime or sub-performers. Awards will prioritize entities conducting work in the United States. Active SAM.gov registration and a Unique Entity Identifier (UEI) are required. No specific set-aside is designated.
Submission & Evaluation
Proposers must first submit a Solution Summary using the provided "Attachment A" template, limited to 6-8 pages depending on the number of TAs addressed. Invited proposers will then submit a full proposal, including written materials and an in-person pitch. Evaluation criteria include scientific and technical merit, feasibility, innovation, and proposer capabilities. Budget reasonableness will be assessed for full proposals. Industry cost share is encouraged, particularly in later phases (10% in Phase 2, 50% in Phase 3 for TA1).
Additional Notes
Activities out of scope include general wellness tracking, solely pharmacologic treatment, or non-personalized interventions.